

Stefan Sleijfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2608429/publications.pdf>

Version: 2024-02-01

160
papers

5,227
citations

109321

35
h-index

106344

65
g-index

163
all docs

163
docs citations

163
times ranked

9088
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach. <i>Journal of Digital Imaging</i> , 2022, 35, 127-136.	2.9	14
2	Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Throughout Disease Progression. <i>JCO Precision Oncology</i> , 2022, 6, e2100190.	3.0	5
3	Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis. <i>Cancers</i> , 2022, 14, 709.	3.7	8
4	Prognostic Value of Circulating Tumor Cell Characteristics May Be Biased by Their Quantity. <i>Journal of Clinical Oncology</i> , 2022, 40, 519-520.	1.6	2
5	The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. <i>BMC Cancer</i> , 2022, 22, 165.	2.6	8
6	In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1527-1535.	1.0	7
7	Abstract P2-01-17: Circulating tumor cell count and levels of circulating tumor DNA are complementary prognostic biomarkers in metastatic breast cancer - A pilot study. <i>Cancer Research</i> , 2022, 82, P2-01-17-P2-01-17.	0.9	1
8	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	1.3	1
9	Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review. <i>Cancer Treatment Reviews</i> , 2022, 106, 102384.	7.7	12
10	A pipeline for copy number profiling of single circulating tumour cells to assess inpatient tumour heterogeneity. <i>Molecular Oncology</i> , 2022, 16, 2981-3000.	4.6	6
11	First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 169, 135-145.	2.8	13
12	ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5631.	4.1	4
13	Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 204-214.	5.4	20
14	Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. <i>Molecular Oncology</i> , 2021, 15, 57-66.	4.6	28
15	Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. <i>BMC Cancer</i> , 2021, 21, 315.	2.6	18
16	The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning. <i>Journal of Personalized Medicine</i> , 2021, 11, 257.	2.5	4
17	Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4523-4523.	1.6	2
18	The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)-A Protocol for an International Cohort Study. <i>Cancers</i> , 2021, 13, 3068.	3.7	9

#	ARTICLE	IF	CITATIONS
19	Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. <i>European Journal of Cancer</i> , 2021, 150, 179-189.	2.8	47
20	The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. <i>Nature Communications</i> , 2021, 12, 4612.	12.8	55
21	Adjuvant treatment in patients with melanoma: The planning of scanning. <i>European Journal of Cancer</i> , 2021, 157, 306-307.	2.8	1
22	Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 2798-2806.	7.0	14
23	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. <i>Nature Communications</i> , 2021, 12, 574.	12.8	39
24	High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments. <i>Clinical Epigenetics</i> , 2021, 13, 196.	4.1	10
25	Whole exome sequencing of cell-free DNA – A systematic review and Bayesian individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 83, 101951.	7.7	26
26	High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2~ postmenopausal breast cancer patients treated with everolimus and exemestane. <i>Molecular Oncology</i> , 2020, 14, 490-503.	4.6	14
27	Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6975.	4.1	5
28	Letter to the editor: Comments on –A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation–™. <i>European Journal of Cancer</i> , 2020, 138, 54-56.	2.8	2
29	Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 565031.	2.8	7
30	Active surveillance in desmoid-type fibromatosis: A systematic literature review. <i>European Journal of Cancer</i> , 2020, 137, 18-29.	2.8	21
31	Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer. <i>ESMO Open</i> , 2020, 5, e000619.	4.5	13
32	Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics. <i>European Journal of Radiology</i> , 2020, 131, 109266.	2.6	11
33	Assessing the Desmoid-Type Fibromatosis Patients’s™ Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries. <i>Sarcoma</i> , 2020, 2020, 1-9.	1.3	7
34	Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. , 2020, 8, e000271.		29
35	Bridging the Translational Divide in Oncology: In Vivo Testing of Chemo-sensitivity. <i>Clinical Cancer Research</i> , 2020, 26, 3897-3898.	7.0	0
36	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39

#	ARTICLE	IF	CITATIONS
37	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.7	22
38	Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. <i>Scientific Reports</i> , 2020, 10, 2927.	3.3	8
39	Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples. <i>British Journal of Cancer</i> , 2020, 122, 953-956.	6.4	21
40	MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma. <i>PLoS ONE</i> , 2020, 15, e0228014.	2.5	3
41	CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. <i>Cells</i> , 2020, 9, 124.	4.1	5
42	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. <i>Scientific Reports</i> , 2019, 9, 10677.	3.3	37
43	<i>RAS</i> and <i>BRAF</i> mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested <i>RAS</i> wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2361-2374.	4.6	32
44	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	3.7	21
45	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	21.4	250
46	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 48-54.	2.8	20
47	Self-Seeding Microwells to Isolate and Assess the Viability of Single Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 477.	4.1	10
48	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. <i>Pharmacogenomics Journal</i> , 2019, 19, 473-479.	2.0	9
49	Molecular Comparison of Imatinib-Na ⁺ ve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs. <i>Cancers</i> , 2019, 11, 882.	3.7	9
50	Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. <i>Drug Discovery Today</i> , 2019, 24, 1715-1719.	6.4	10
51	CD45RA+CCR7 ^{hi} CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
52	<i>AR</i> splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel. <i>Molecular Oncology</i> , 2019, 13, 1795-1807.	4.6	23
53	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. <i>Sarcoma</i> , 2019, 2019, 1-11.	1.3	1
54	Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. <i>Surgical Oncology</i> , 2019, 29, 84-89.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. <i>Acta Oncologica</i> , 2019, 58, 872-879.	1.8	11
56	The role of mitochondrial DNA in breast tumors. <i>Drug Discovery Today</i> , 2019, 24, 1202-1208.	6.4	15
57	Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 451-458.	2.5	14
58	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1083-1089.	5.1	27
59	Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study. <i>Oncologist</i> , 2019, 24, e526-e535.	3.7	6
60	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. <i>Nature Communications</i> , 2019, 10, 5251.	12.8	130
61	<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1766-1773.	7.0	117
62	Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β -catenin mutations. <i>European Journal of Surgical Oncology</i> , 2019, 45, 691-698.	1.0	4
63	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 651-658.	3.5	20
64	Novel methods to diagnose leptomeningeal metastases in breast cancer. <i>Neuro-Oncology</i> , 2019, 21, 428-439.	1.2	10
65	Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 109, 12-20.	2.8	58
66	High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. <i>Molecular Oncology</i> , 2019, 13, 392-402.	4.6	37
67	CD276-positive circulating endothelial cells in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 572-572.	1.6	2
68	An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 316-325.	2.8	15
69	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	5.1	32
70	Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 435-445.	2.3	21
71	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	6.4	49
72	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. <i>Clinical Cancer Research</i> , 2018, 24, 2678-2687.	7.0	35

#	ARTICLE	IF	CITATIONS
73	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. <i>Acta Oncologica</i> , 2018, 57, 1117-1126.	1.8	11
74	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2018, 12, 48-57.	4.6	52
75	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	3.7	27
76	EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. <i>European Journal of Cancer</i> , 2018, 88, 87-91.	2.8	7
77	Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 95-105.	2.5	37
78	EXTH-03. LOCAL ONCOLYTIC ADENOVIRUS TREATMENT AFFECTS BOTH THE INNATE AND ADAPTIVE ARMS OF THE IMMUNE SYSTEM AND PROVIDES AN AVENUE FOR ENHANCING IMMUNOTHERAPIES FOR GBM. <i>Neuro-Oncology</i> , 2018, 20, vi85-vi85.	1.2	0
79	Evidence on the cost of breast cancer drugs is required for rational decision making. <i>Ecancermedicalscience</i> , 2018, 12, 825.	1.1	3
80	Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers. <i>Cancers</i> , 2018, 10, 500.	3.7	7
81	The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. <i>Cancers</i> , 2018, 10, 134.	3.7	18
82	Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. <i>Quality of Life Research</i> , 2018, 27, 3097-3111.	3.1	17
83	Prognostic value of intra-tumoral CD8 ⁺ /FoxP3 ⁺ lymphocyte ratio in patients with resected colorectal cancer liver metastasis. <i>Journal of Surgical Oncology</i> , 2018, 118, 68-76.	1.7	46
84	Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.. <i>Journal of Clinical Oncology</i> , 2018, 36, 92-92.	1.6	69
85	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. <i>Oncotarget</i> , 2018, 9, 19283-19293.	1.8	54
86	The complete genomic landscape of metastatic prostate cancer pinpoints clinically targetable subgroups.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5014-5014.	1.6	0
87	Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21239-e21239.	1.6	0
88	Correlation between nivolumab exposure and treatment outcome in NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9057-9057.	1.6	1
89	Androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1087-1087.	1.6	0
90	PD-L1, Galectin-9 and CD8 ⁺ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. <i>Onc Immunology</i> , 2017, 6, e1273309.	4.6	117

#	ARTICLE	IF	CITATIONS
91	Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions. <i>Molecular Oncology</i> , 2017, 11, 295-304.	4.6	123
92	Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 4735-4743.	7.0	14
93	Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. <i>International Journal of Cancer</i> , 2017, 141, 572-582.	5.1	53
94	Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA. <i>Scientific Reports</i> , 2017, 7, 2136.	3.3	7
95	Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 511-519.	4.4	5
96	First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy. <i>Oncologist</i> , 2017, 22, 901-909.	3.7	18
97	Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. <i>Clinical Sarcoma Research</i> , 2017, 7, 2.	2.3	8
98	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. <i>European Journal of Cancer</i> , 2017, 75, 33-40.	2.8	22
99	Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer. <i>JAMA Oncology</i> , 2017, 3, 501.	7.1	23
100	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , 2017, 86, 226-232.	2.8	13
101	Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure. <i>Clinical Pharmacokinetics</i> , 2017, 56, 305-310.	3.5	11
102	Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. <i>Breast</i> , 2017, 31, 9-15.	2.2	109
103	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 52, 33-40.	7.7	75
104	Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. <i>PLoS ONE</i> , 2017, 12, e0183155.	2.5	12
105	Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 276-276.	1.6	21
106	Rates of survival throughout the years in soft tissue sarcoma with synchronous metastases: Results of a population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11068-11068.	1.6	0
107	Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. <i>Oncotarget</i> , 2016, 7, 43412-43418.	1.8	30
108	T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients. <i>Frontiers in Immunology</i> , 2016, 7, 648.	4.8	26

#	ARTICLE	IF	CITATIONS
109	Plasma IFN- γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells. <i>Clinical Immunology</i> , 2016, 169, 107-113.	3.2	10
110	Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. <i>Urology</i> , 2016, 95, 121-127.	1.0	34
111	Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered. <i>European Journal of Human Genetics</i> , 2016, 24, 1496-1500.	2.8	22
112	Affordability of drugs used in oncology health care. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 331-332.	27.6	5
113	The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 46, 42-50.	7.7	24
114	Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells—a completed study overview. <i>Biochemical Society Transactions</i> , 2016, 44, 951-959.	3.4	115
115	MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. <i>Journal of Immunology</i> , 2016, 197, 2541-2552.	0.8	20
116	The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. <i>Oncologist</i> , 2016, 21, 1396-1409.	3.7	147
117	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. <i>Neoplasia</i> , 2016, 18, 647-653.	5.3	44
118	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	2.6	25
119	Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. <i>European Journal of Cancer</i> , 2016, 56, 101-106.	2.8	16
120	Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59058-59069.	1.8	37
121	Mitochondrial DNA content in breast cancer: Impact on <i>in vitro</i> and <i>in vivo</i> phenotype and patient prognosis. <i>Oncotarget</i> , 2016, 7, 29166-29176.	1.8	33
122	Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, e246-e249.	3.5	13
123	Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 920-925.	2.0	2
124	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
125	Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2015, 41, 187-196.	7.7	47
126	mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. <i>Molecular Oncology</i> , 2015, 9, 920-932.	4.6	37

#	ARTICLE	IF	CITATIONS
127	Are Immune Signatures a Worthwhile Tool for Decision Making in Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, 673-675.	1.6	5
128	Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area. <i>Oncologist</i> , 2015, 20, 241-242.	3.7	8
129	Adoptive T-cell therapy: a need for standard immune monitoring. <i>Immunotherapy</i> , 2015, 7, 513-533.	2.0	17
130	Development and validation of an UPLCâ€“MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 416-425.	2.8	16
131	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. <i>Cancer Letters</i> , 2015, 362, 36-44.	7.2	41
132	Lysosomal Sequestration Determines Intracellular Imatinib Levels. <i>Molecular Pharmacology</i> , 2015, 88, 477-487.	2.3	30
133	Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib. <i>Hypertension</i> , 2015, 66, 543-549.	2.7	38
134	Current clinical trials for advanced osteosarcoma and soft tissue sarcoma. <i>Current Opinion in Oncology</i> , 2014, 26, 434-439.	2.4	12
135	The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. <i>European Journal of Cancer</i> , 2014, 50, 972-980.	2.8	20
136	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. <i>Clinical Sarcoma Research</i> , 2014, 4, 7.	2.3	47
137	Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib. <i>Hypertension</i> , 2014, 64, 1282-1289.	2.7	78
138	Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. <i>Endocrine-Related Cancer</i> , 2014, 21, 653-661.	3.1	39
139	Pazopanib in uterine sarcoma (Uts): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10579-10579.	1.6	2
140	Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11017-11017.	1.6	0
141	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10573-10573.	1.6	2
142	A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2522-2522.	1.6	5
143	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOC) side study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22106-e22106.	1.6	1
144	Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS): Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10553-10553.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Phase I study of cisplatin (cDDP)/hyperthermia (HT)/lapatinib (Lap) in patients (pts) with recurrent carcinoma of the uterine cervix (rCC) in previously irradiated area (PIA).. Journal of Clinical Oncology, 2013, 31, e16504-e16504.	1.6	0
146	mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).. Journal of Clinical Oncology, 2013, 31, 11045-11045.	1.6	0
147	Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).. Journal of Clinical Oncology, 2012, 30, 2593-2593.	1.6	20
148	Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 2596-2596.	1.6	5
149	How to Decide Whether to Offer and Use "Nonstandard" Therapies in Patients with Advanced Sarcomas and Gastrointestinal Stromal Tumors: Global Variations in Clinical Practice, Assessment, and Access to Therapies in Diseases with Limited Incidence and Data. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 645-650.	3.8	3
150	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. Clinical Cancer Research, 2011, 17, 3600-3618.	7.0	207
151	Clinical value of circulating tumor cells in breast cancer. Nature Reviews Clinical Oncology, 2011, 8, 696-698.	27.6	6
152	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. European Journal of Cancer, 2010, 46, 72-83.	2.8	224
153	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer "Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). Journal of Clinical Oncology, 2009, 27, 3126-3132.	1.6	611
154	Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Research and Treatment, 2009, 118, 455-468.	2.5	171
155	Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas. Oncologist, 2008, 13, 1193-1200.	3.7	22
156	Circulating tumour cell detection on its way to routine diagnostic implementation?. European Journal of Cancer, 2007, 43, 2645-2650.	2.8	101
157	Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Oncology, 2005, 2, 70-71.	4.3	2
158	The potential of statins as part of anti-cancer treatment. European Journal of Cancer, 2005, 41, 516-522.	2.8	92
159	Thalidomide in solid tumours: the resurrection of an old drug. European Journal of Cancer, 2004, 40, 2377-2382.	2.8	40
160	Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British Journal of Cancer, 0, , .	6.4	2